Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| DT DTILPrecision BioSciences | $8.85+1.5% | $244.3M | 8 assetsPhase 1/2 | ECUR-506Phase 1/2 · Data readout | |
| DV DVAXDynavax Technologies | $15.50+0.0% | $1.82B | 10 assetsPhase 1/2 |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| DW DWTXDogwood Therapeutics | $2.49+6.9% | $84.6M | 4 assetsPhase 2b | HalneuronPhase 2b · Data readout |
| DY DYNDyne Therapeutics | $26.10+0.5% | $4.87B | 3 assetsPDUFA | DYNE-251PDUFA · Approval decision |
| EB EBSEmergent BioSolutions Inc | $5.08+5.4% | $260.5M | 16 assetsStage unavailable | No dated catalyst |
| ED EDITEditas Medicine | $3.11+5.8% | $477.6M | 4 assetsStage unavailable | No dated catalyst |
| ED EDSAEdesa Biotech | $4.43-6.9% | $42.7M | 3 assetsStage unavailable | No dated catalyst |
| EG EGRXEagle Pharmaceuticals | $0.25+0.0% | $3.3M | 7 assetsStage unavailable | No dated catalyst |
| EI EIKNEikon Therapeutics | $11.39+6.0% | $616.9M | 7 assetsPhase 2/3 | EIK1005Phase 1/2 · Data readout |
| EL ELDNEledon Pharmaceuticals | $3.45-2.0% | $280.4M | 9 assetsPhase 1b | No dated catalyst |
| EL ELEVElevation Oncology | $0.37+0.0% | $21.6M | 2 assetsStage unavailable | No dated catalyst |
| EL ELOXEloxx Pharmaceuticals | $20.98+16.3% | $72.1M | 5 assetsStage unavailable | No dated catalyst |
| EL ELTXElicio Therapeutics | $3.04-1.1% | $79.9M | 3 assetsPhase 3 | No dated catalyst |
| EL ELVNEnliven Therapeutics, Inc | $59.82+1.5% | $4.38B | 3 assetsStage unavailable | No dated catalyst |
| EN ENDPEndo Pharmaceuticals | — | — | 4 assetsStage unavailable | No dated catalyst |
| EN ENGNenGene | $1.78+0.6% | $119.2M | 1 assetsPhase 2 | Detalimogene (EG-70)Phase 2 · Data readout |
| EN ENLVEnlivex Therapeutics | $1.47-2.0% | $25.7M | 10 assetsPhase 2 | Allocetra (Immunotherapy)Phase 2 · Data readout |
| EN ENSCEnsysce Biosciences | $0.37-1.2% | $7.3M | 3 assetsStage unavailable | No dated catalyst |
| EN ENTAEnanta Pharmaceuticals | $13.47+2.6% | $392.3M | 9 assetsPhase 1 | EDP-978 (KIT Inhibitor)Phase 1 · Data readout |
| EN ENTXEntera Bio Ltd | $3.23+0.3% | $559.2M | 4 assetsPhase 1 | OPK-88006 (GLP-1/Glucagon Agonist)Phase 1 · Data readout |
| EO EOLSEvolus | $8.39+0.5% | $554.2M | 3 assetsStage unavailable | No dated catalyst |
| EP EPIXESSA Pharma | $0.20+0.0% | $9.5M | 3 assetsStage unavailable | No dated catalyst |
| EQ EQEquillium | $2.31+1.8% | $146.5M | 7 assetsStage unavailable | No dated catalyst |
| ER ERASErasca | $17.63+3.2% | $6.17B | 12 assetsPhase 1 | ERAS-4001Phase 1 · Data readout |
| ER ERNAErnexa Therapeutics | $4.86+5.3% | $5.7M | 1 assetsStage unavailable | No dated catalyst |
| ES ESPREsperion | $3.18+0.0% | $819.5M | 5 assetsStage unavailable | No dated catalyst |
| ET ETNB89bio Inc. | $14.84+0.0% | $2.20B | 3 assetsPhase 3 | Pegozafermin (BIO89-100) (FGF21 analog) Phase 3 · Data readout |
| ET ETONEton Pharmaceuticals | $63.47+5.9% | $1.81B | 23 assetsPhase 1 | ET-700 (Extended-Release Drug)Phase 1 · Data readout |
| EV EVAXEvaxion Biotech | $3.31+0.9% | $27.6M | 5 assetsPhase 2 | EVX-01 + pembrolizumabPhase 2 · Data readout |
| EV EVFMEvofem Biosciences | $0.01+0.0% | $1.1M | 4 assetsStage unavailable | No dated catalyst |
| EV EVLOEvelo Biosciences Inc | $0.00+0.0% | $1,898 | 5 assetsStage unavailable | No dated catalyst |
| EV EVMNEvommune | $14.02+3.3% | $508.8M | 4 assetsPhase 2b | EVO756 (MRGPRX2 Antagonist)Phase 2b · Data readout |
| EW EWTXEdgewise Therapeutics | $44.18+2.1% | $4.80B | 8 assetsPhase 2 | Sevasemten (EDG-5506)Phase 2 · Data readout |
| EX EXAIExscientia | $4.84+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| EX EXELExelixis Inc | $54.08+0.7% | $13.40B | 18 assetsPDUFA | Zanzalintinib + atezolizumabPDUFA · Approval decision |
| EY EYPTEyePoint pharmaceuticals | $5.32-1.5% | $446.0M | 5 assetsPhase 3 | DURAVYU™ (vorolanib intravitreal insert) (EYP-1901)Phase 3 · Data readout |
| FA FATEFate Therapeutics | $2.33-4.9% | $279.2M | 17 assetsPhase 1 | FT819 (CAR-19, TCR-KO)Phase 1 · Data readout |
| FB FBIOFortress Biotech | $2.87+3.6% | $95.7M | 15 assetsPhase 2 | TriplexPhase 2 · Data readout |
| FB FBRXForte Biosciences Inc | $76.92+0.0% | $1.63B | 4 assetsPhase 2 | FB102Phase 1 · Data readout |
| FD FDMT4D Molecular Therapeutics | $15.83-1.7% | $874.5M | 8 assetsPhase 3 | 4D-150Phase 3 · Data readout |